1 School of Pharmacy, University of Wisconsin, Madison, USA.
4 Department of Family Medicine and Community Health, University of Wisconsin, Madison, USA.
J Psychopharmacol. 2018 Jul;32(7):770-778. doi: 10.1177/0269881118780713. Epub 2018 Jun 27.
The aim of the current study was to investigate the relationship between escalating higher doses of psilocybin and the potential psilocybin occasioned positive subjective effects.
Healthy participants ( n=12) were given three escalating doses of oral psilocybin (0.3 mg/kg; 0.45 mg/kg; 0.6 mg/kg) or (18.8-36.6 mg; 27.1-54.0 mg; 36.3-59.2 mg) a minimum of four weeks apart in a supervised setting. Blood and urine samples, vital signs, and electrocardiograms were obtained. Subjective effects were assessed using the Mystical Experience Questionnaire and Persisting Effects Questionnaire.
There was a significant linear dose-related response in Mystical Experience Questionnaire total score and the transcendence of time and space subscale, but not in the rate of a complete mystical experience. There was also a significant difference between dose 3 compared to dose 1 on the transcendence of time and space subscale, while no dose-related differences were found for Mystical Experience Questionnaire total scores or rate of a mystical experience. Persisting Effects Questionnaire positive composite scores 30 days after completion of the last dose were significantly higher than negative composite scores. Persisting Effects Questionnaire results revealed a moderate increase in sense of well-being or life satisfaction on average that was associated with the maximum Mystical Experience Questionnaire total score. Pharmacokinetic measures were associated with dose but not with Mystical Experience Questionnaire total scores or rate of a mystical experience.
High doses of psilocybin elicited subjective effects at least as strong as the lower doses and resulted in positive persisting subjective effects 30 days after, indicating that a complete mystical experience was not a prerequisite for positive outcomes.
本研究旨在探讨递增较高剂量裸盖菇素与潜在的裸盖菇素引发的积极主观效应之间的关系。
将健康参与者(n=12)在监督环境下至少间隔四周分别给予三次递增剂量的口服裸盖菇素(0.3mg/kg;0.45mg/kg;0.6mg/kg)或(18.8-36.6mg;27.1-54.0mg;36.3-59.2mg)。采集血液和尿液样本、生命体征和心电图。使用神秘体验问卷和持续效应问卷评估主观效应。
神秘体验问卷总分和超越时空子量表呈显著线性剂量相关反应,但完全神秘体验的比率没有。与剂量 1 相比,剂量 3 时在超越时空子量表上也存在显著差异,而神秘体验问卷总分或完全神秘体验的比率没有剂量相关差异。最后一次剂量后 30 天,持续效应问卷积极综合评分显著高于消极综合评分。持续效应问卷结果显示,平均幸福感或生活满意度呈中度增加,与神秘体验问卷总分的最大值相关。药代动力学测量与剂量相关,但与神秘体验问卷总分或完全神秘体验的比率无关。
高剂量裸盖菇素引起的主观效应至少与低剂量一样强烈,并在最后一次剂量后 30 天产生积极的持续主观效应,表明完全的神秘体验不是积极结果的先决条件。